A novel study reported that peroxisome proliferator-activated receptor-γ (PPARγ) acts as an antagonist of NR4A1 and can ubiquitination and degradation of NR4A1 through ubiquitin enzyme tripartite motif 13 (TRIM13); this process interferes with the interaction of NR4A1 and SWI/SNF complex, and recruit to the promoter of fatty acid transporters CD36 and FABP4 to inhibit their transcription, which blocked fatty acid uptake to suppress cancer cell proliferation (41) (Figure 5). Here, NR4A1 is linked to cancer.